BMS noted that the trial was not structured to independently evaluate Opdivo plus Yervoy against lenvatinib or sorafenib ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line treatment for adults with unresectable or metastatic HCC.

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.